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Endothelin-1 (ET-1) is a critical autocrine and paracrine regulator of cardiac physiology and pathology. Produced locally within
the myocardium in response to diverse mechanical and neurohormonal stimuli, ET-1 acutely modulates cardiac contractility.
During pathological cardiovascular conditions such as ischaemia, left ventricular hypertrophy and heart failure, myocyte
expression and activity of the entire ET-1 system is enhanced, allowing the peptide to both initiate and maintain maladaptive
cellular responses. Both the acute and chronic effects of ET-1 are dependent on the activation of intracellular signalling
pathways, regulated by the inositol-trisphosphate and diacylglycerol produced upon activation of the ETA receptor.
Subsequent stimulation of protein kinases C and D, calmodulin-dependent kinase II, calcineurin and MAPKs modifies the
systolic calcium transient, myofibril function and the activity of transcription factors that coordinate cellular remodelling. The
precise nature of the cellular response to ET-1 is governed by the timing, localization and context of such signals, allowing
the peptide to regulate both cardiomyocyte physiology and instigate disease.
LINKED ARTICLES
This article is part of a themed section on Endothelin. To view the other articles in this section visit http://dx.doi.org/
10.1111/bph.2013.168.issue-1
Abbreviations
AngII, angiotensin II; CICR, calcium-induced-calcium release; Cn, calcineurin; ECC, excitation-contraction-coupling;
IICR, IP3-induced calcium release; IP3R, inositol triphosphate receptor; MyBP-C, myosin binding protein C; RyR,
ryanodine receptor; TnI, troponin I
Introduction
Endothelin (ET)-1, ET-2 and ET-3 are a family of cyclic 21
amino acid peptides. The peptides are encoded within three
separate yet highly conserved genes located on chromosomes
6, 1 and 20 in humans respectively (Inoue et al., 1989). ET-1
is the most well characterized member of this family. The
peptide was initially isolated from the culture supernatant of
porcine aortic endothelial cells and identified as a protease-
sensitive vasoconstrictor. It remains the most potent vasoac-
tive substance identified to date (Yanagisawa et al., 1988),
performing an important function in the regulation of vas-
cular smooth muscle tone. ET-1 also mediates effects on other
cell types. Here, we discuss the role of ET-1 in the heart. We
will focus on the actions of ET-1 on cardiac muscle and
describe how the ET system contributes to cardiac regulation
and autoregulation during health and disease.
ET-1 in the heart
Throughout life, ET-1 plays key roles in many aspects of
cardiac physiology and pathology. It is involved in control-
ling aortic arch formation during development (Kurihara
et al., 1995), is required for cardiomyocyte survival and pre-
vents myocyte loss during ageing (Zhao et al., 2006). In the
adult, ET-1 modulates coronary blood flow by regulation of
vascular tone. Furthermore, by acting on its receptors
expressed by atrial and ventricular myocytes, the peptide
modulates cardiac muscle function directly (Hirata et al.,
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1989). The effects of ET-1 on the heart are observed over
distinct and wide timescales. Acutely (within minutes), ET-1
modulates muscle contractility and induces arrhythmias (Bal-
togiannis et al., 2005), whereas over longer time scales (days
to weeks), the peptide induces cardiomyocyte growth. The
long-term effects of ET-1 are associated with maladaptive
hypertrophic remodelling of the heart (Yorikane et al., 1993)
and its progression to failure (Francis et al., 1990). Hence,
ET-1 is considered to contribute to both the aetiology and
pathology of these conditions. Indeed, the circulating plasma
level of ET-1 is positively correlated with severity of cardiac
disease and thus is a reliable prognostic indicator of future
heart failure (Selvais et al., 2000; Zolk et al., 2002).
Paracrine/autocrine ET-1 in regulation
of cardiac function
Further contributing to its significant role in modulating
cardiomyocyte function, ET-1 is synthesized and secreted by
the myocytes (Nunez et al., 1990; Firth and Ratcliffe, 1992;
Suzuki et al., 1993), fibroblasts (Fujisaki et al., 1995) and
endothelial cells (Kedzierski and Yanagisawa, 2001) of the
heart. The presence of the machinery for both the production
and detection of ET-1 within the myocardium generates a
local autocrine and paracrine ET-1 system, providing a tightly
coupled and regulated means of control (Pikkarainen et al.,
2006; Higazi et al., 2009). Supporting this notion, ET-1
production/secretion is signal-responsive and contributes to
both normal adaptive physiological responses and to the
induction and progression of pathology. During physiology,
myocyte-secreted ET-1 is reported to contribute to stretch-
induced enhancement of contractility, which can occur
during periods of increased workload (Pikkarainen et al.,
2006). In this context, ET-1 secretion/production is either
directly stimulated or induced in response to AngII, which is
also secreted by the stretched myocyte (Sadoshima et al.,
1993; Yamazaki et al., 1996; Pikkarainen et al., 2006; Cin-
golani et al., 2011). As a result, contractility is enhanced to
accommodate for the change in cardiac demand. This mecha-
nism may explain the slow force response or Anrep effect
observed in stretched atrial preparations (Kockskämper et al.,
2008a). Indeed, many of the cardiac effects of AngII are abro-
gated by ET receptor inhibition (Ito et al., 1993). Should the
initiating stimulus and thus ET-1 secretion persist, hypertro-
phy may result (Yamazaki et al., 1996). The acute effect of
ET-1 is therefore a prequel to its longer term effect on cardiac
remodelling (Cingolani et al., 2011). In aged individuals, the
plasma concentration of ET-1 is elevated (Maeda et al., 2003),
hence the importance of ET-1-induced cardiovascular effects
increases with time. Furthermore, cardiomyocyte ET-1 gen-
eration is increased following ischaemia (Serneri et al., 2000),
during the cardiac hypertrophic response (Yorikane et al.,
1993; Zolk et al., 2002; Mayyas et al., 2010) and as a result of
heart failure (Francis et al., 1990). This increased ET-1 contrib-
utes to pathologies such as arrhythmia and the initiation and
development of cardiac remodelling, the incidence of which
increases with age (Lakatta and Levy, 2003b). Increased
expression of ET-1 has been observed at both the mRNA level
of pre-pro-ET-1 and the protein level of the mature peptide
itself (Arai et al., 1995; Kobayashi et al., 1999; Zhao et al.,
2006), suggesting that increased transcription contributes to
enhanced ET-1 production. This is accompanied by increased
activity of the processing mechanisms that produce the
mature peptide. Expression and activity of endothelin con-
verting enzyme 1a (ECE1a) is up-regulated in human failing
hearts and animal models of congestive heart failure (Ergul
et al., 2000a; 2000b), expediting the processing of big-ET-1
into mature ET-1. In conjunction with the increased level of
ET-1 peptide, expression of the ETA receptor by ventricular
myocytes is enhanced during disease (Arai et al., 1995; Pieske
et al., 1999; Baltogiannis et al., 2005; Harzheim et al., 2010).
Thus, under disease-associated conditions, mechanisms of
ET-1 production and detection are up-regulated in a myocyte-
centric manner, providing an entirely local mechanism for
the pathological effects of ET-1.
ET receptors
ET-1 elicits its effects by association with one or both of its
receptor isoforms, the ETA and ETB receptors (Arai et al., 1990;
Sakurai et al., 1990; Webb, 1991; Yorikane et al., 1993; Alex-
ander et al., 2011). Both receptor isoforms are classical GPCRs
comprising 7 a-helical transmembrane spanning domains, an
extracellular N-terminal domain and intracellular C-terminal
domain. The intracellular C-terminal domain and loops
between the transmembrane segments interact with heterot-
rimeric G-proteins composed of Ga, b and g subunits. Acti-
vation of these receptors stimulates multiple intracellular
signalling pathways and mediates diverse cellular effects
(Ishikawa et al., 1988a; 1988b; Moravec et al., 1989). The rela-
tive abundance of ET receptors varies across the chambers
and regions of the normal healthy heart, with the number of
ET-1 binding sites in atrial cells far exceeding those found in
ventricular cells (Molenaar et al., 1993). Functionally, the ETA
and ETB receptors exhibit several key differences. Although
the affinity of both ET receptors for ET is subnanomolar, the
ETA receptor exhibits a higher affinity for ET-1 over ET-2 or
ET-3 (Hosoda et al., 1991), whilst the ETB receptor binds non-
selectively to each of the three ET isoforms (Sakurai et al.,
1990). The downstream signals activated following engage-
ment of the ETA receptor and ETB receptor also differ. Both
receptors can couple to multiple G-proteins but the particular
G-protein repertoire that each isoform engages may vary,
governing the pattern of downstream pathways activated.
The ETA receptor interacts with Gaq/11 (Aramori and Nakani-
shi, 1992), Gas (Eguchi et al., 1993b; Yamazaki et al., 1996)
and Ga12 activating polyphosphoinositide hydrolysis and
production of inositol-(1,4,5)-triphosphate (IP3), diacylglyc-
erol (DAG) and cAMP (Griendling et al., 1989; Takuwa et al.,
1990; Serneri et al., 2000). The ETB receptor also couples to
Gaq/11. However, in contrast to the ETA receptor, it preferen-
tially interacts with Gai/o and Ga13 (Eguchi et al., 1993b;
Gohla et al., 1999). Consequently, activation of the ETB recep-
tor is associated with inhibition of cAMP accumulation as
well as stimulation of polyphosphoinositide hydrolysis
(Eguchi et al., 1993a). Although the heart expresses both
receptor isoforms, in cardiomyocytes the ETA receptor pre-
dominates accounting for greater than 80% of ET binding
sites (Allen et al., 2003).
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The most well established mechanisms of ETA receptor-
dependent signalling in cardiomyocytes concern those regu-
lated downstream of Gaq/11. Inhibition of Gaq/11 prevents
activation of ET-1 dependent signalling pathways in rat adult
ventricular myocytes (AVM), whilst reducing the activity of
either Ga12/13 or Gai/o does not produce comparable effects
(Snabaitis et al., 2005). Furthermore, ET-1-dependent signal-
ling is enhanced by knockdown of the GTPase activating
protein regulator of G-protein signalling 2 (RGS2), which
negatively regulates GTP-bound Gaq/11 by enhancing its GTP
hydrolysing properties (Zhang et al., 2006). The downstream
effects of Gaq/11 activation are mediated through activation
of PLC enzymes, which catalyse the hydrolysis of
phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) to produce
membrane-associated DAG and soluble IP3 (Wu et al., 1992).
Cardiomyocytes express multiple PLC isoforms, with PLCb1
and B3 showing Gaq/11-dependent activity. ET-1 stimulation of
cultured neonatal rat ventricular myocytes (NRVM) leads to
phosphoinositide hydrolysis within seconds (Clerk and
Sugden, 1997). The rapid increase in IP3 and DAG activates
multifarious downstream signalling pathways, including
those regulated by calcium, small G-proteins and kinase cas-
cades (Figure 1). In addition, ET-1 stimulates nicotinamide
adenine dinucleotide phosphate oxidase (NADPH oxidase)
(De Giusti et al., 2008) and production of reactive oxygen
species (ROS) (Cheng et al., 1999). These pathways perform
important roles in regulation of cardiomyocyte contractility,
pacemaking and remodelling.
Terminating ET-1 signalling
In order to limit the effects of ET-1 on the heart, signalling
from ET receptors must be tightly regulated. The ETA receptor
forms a very high affinity interaction with ET-1 and the rate
of disassociation of ligand/receptor complex is slow; hence,
this process is not straightforward (Hilal-Dandan et al., 1997).
Indeed, the resistance of the ET-1/ETA receptor complex to
acid or exposure to inhibitor has led to the proposal that
ET-1/ETA receptor binding is quasi-irreversible, possibly as a
result of covalent binding of ET-1 to the receptor. Thus, it is
likely that the receptor is internalized in a ligand-bound state
Figure 1
Signalling pathways activated downstream of the ETA receptor in cardiomyocytes. ET-1 binds to the Gaq-coupled ETA receptor inducing production
of IP3 and DAG. These second messengers activate protein kinase cascades, ROS production and IP3-induced calcium release. Following ET-1
binding, the ET-1-ETA receptor complex is internalized in a GRK3-b-arrestin dependent manner. b-arrestin has been postulated to induce activation
of MAPK cascades.
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and that internalization of this complex, rather than ET-1
dissociation, determines the duration of the ET-1 response.
Indeed, an association of ET-1 with the ETA receptor within
the endosome for up to 2 h has been reported (Chun et al.,
1994; 1995). It is unclear whether ET-1 continues to signal via
the ETA receptor when internalized in this manner but this
hypothesis could explain certain of the observed effects of
ET-1- stimulation. Co-localization of internalized ET-1-ETA
receptor with caveolar domains may aid interaction with
G-proteins, enabling ET-1-ETA receptor signalling to persist
(Chun et al., 1994). Furthermore, ET-1-ETA receptor complex
internalization is GRK (G-protein receptor kinase)-b-arrestin
dependent (Freedman et al., 1997). GRKs 2, 3 and 5 are
expressed in cardiac myocytes (Vinge et al., 2001) with GRK2
activity and expression being up-regulated in heart failure –
an adaptation that limits b-adrenergic signalling (Ping et al.,
1997). In AVMs, GRK3 targets the ETA receptor and inhibition
of GRK3 in AVM enhances ET-1 induced signalling, suggest-
ing that this kinase is important for attenuation of the ET-1
response (Vinge et al., 2007). Following GRK-dependent
phosphorylation, recruitment of b-arrestins to activated
receptors targets them for internalization. However,
b-arrestin is also implicated in the activation of the MAPK
cascade (Lefkowitz and Shenoy, 2005). Given these potential
mechanisms of alternative and persistent ET-1-induced sig-
nalling, it appears that a simple model of ET-1-GPCR binding
and agonist-induced desensitization cannot fully account for
the cellular effects of ET-1.
Interestingly, internalized ETA receptor and ETB receptor
are targeted to different intracellular compartments after
stimulation with ET-1. The ETA receptor co-localizes with the
pericentriolar recycling compartment and can be recycled to
the plasmalemma so that cellular ET-1 sensitivity is main-
tained. In contrast, ETB receptor are targeted to lysosomes and
degraded after agonist-induced internalization. The lyso-
somal fate of the internalized ET-1–ETB receptor complex
provides a mechanism for clearance of the peptide (Attinà
et al., 2005). Exemplifying this, deletion of the ETB receptor in
mice impairs ET-1 clearance and selective pharmacological
blockade of this isoform increases the circulating concentra-
tion of ET-1 (Gariepy et al., 2000; Kelland et al., 2010). The
vasculature of the lung provides the major site of clearance of
ET-1 from plasma (Dupuis et al., 1996), with approximately
80% of the peptide being removed from the bloodstream by
the ETB receptors expressed by pulmonary endothelial cells.
Efficient removal of the peptide via this mechanism generates
a half-life for ET-1 in the circulation of less than 5 min and
maintains the plasma concentration of the peptide in healthy
individuals at approximately 1 pM (Kedzierski and Yanagi-
sawa, 2001), significantly below its activity threshold.
However, local ET-1 concentration at sites of ET-1 production
and release is expected to be much higher, raising the level of
the peptide to that which can modulate cardiac function.
ET-1 in cardiac pacemaking
and contractility
Cardiac contraction during systole is initiated by an action
potential generated following automatic depolarization of
the pacemaking SA node. From the SA node, the action
potential propagates across the atria and induces contraction.
Following a pause at the atrio-ventricular node, the action
potential is rapidly conducted to the apex of the heart by
specialized Purkinje fibres. Subsequent spreading of the
action potential throughout the ventricles induces contrac-
tion and thus expels blood into the aorta. At the molecular
level, the mechanism that links membrane excitation and
myocyte contraction is termed excitation-contraction cou-
pling (ECC) (Figure 2) (Bers, 2002; Fearnley et al., 2011). This
process is initiated by the depolarization-induced opening of
L-type voltage-gated calcium channels (also known as dihy-
dropyridine receptors), generating the ICa,L current. Calcium
entry through these channels generates a much larger release
of calcium from the sarcoplasmic reticulum (SR) via the
ryanodine receptor (RyR2), in a process termed ‘calcium-
induced-calcium-release’ (CICR) (Fabiato, 1983; Roderick
et al., 2003). This calcium binds to the contractile apparatus
and induces cellular shortening. To terminate systole and
allow relaxation, calcium is extruded from the cell or
re-sequestered in the SR. Synchronous release of calcium
throughout the ventricular myocyte is achieved as a conse-
quence of the highly specialized subcellular structure of the
cell. The sarcolemma is extensively invaginated to form the
t-tubular network; hence, depolarizing action potentials can
spread into the depths of the cell and induce coordinated
cellular contraction. Furthermore, the L-type calcium
channel and RyR2 are co-localized within specialized struc-
tures known as the cardiac dyads, facilitating CICR.
ET-1 has an established role in the regulation of cardiac
contractility, in particular as a positive inotrope (Ishikawa
et al., 1988b; Moravec et al., 1989; Shah et al., 1989). Other
effects upon the heart include negative inotropy, arrhythmo-
genesis, decreased relaxation (lusitropy) and chronotropy
(Ishikawa et al., 1988a; Li et al., 2005). Despite these well-
described aspects of ET-1 in cardiac biology, controversy
remains regarding the effects of ET on cardiac function, its
mechanism(s) of action and the specific molecular targets
involved. A number of factors contribute to the apparent
diversity of responses reported, although variable expression
levels of ET receptors account for many of the discrepancies.
For example, responses are different between species and vary
with age. ET-1 does not exert an inotropic effect in adult mice
and dogs, which have low levels of ET receptor expression
(Takanashi and Endoh, 1991; Nishimaru et al., 2007).
However, in neonatal mice, where ET receptors are more
abundant, inotropic responses to ET-1 are observed (Nagasaka
et al., 2003). Moreover, the origin of the cardiac preparation
studied is also a significant determinant of the response
(Moravec et al., 1989). This is not surprising given that the
distribution and abundance of ET receptor isoforms varies
across the chambers of the heart (Molenaar et al., 1993;
Russell and Davenport, 1996). Further diversity is provided by
the experimental preparation – intact heart, chamber muscle
strips or isolated cells.
Due to greater receptor abundance in the atria, the effects
of ET-1 are most well established in this chamber (Ishikawa
et al., 1988b; Vigne et al., 1989; Molenaar et al., 1993). The
atrial response to ET-1 (e.g. in rat, rabbit and guinea pig) is
characterized by an initial negative inotropic phase (first 1–2
min), followed by a slowly developing and persistent positive
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inotropic phase (Takanashi and Endoh, 1991; Bootman et al.,
2007). Although cAMP independent, the positive inotropic
effect of ET-1 in the atria can reach levels comparable to that
induced by the catecholamines (Vigne et al., 1989). The
cardiac ventricle also exhibits a positive inotropic response to
ET-1, albeit at a substantially reduced magnitude (Takanashi
and Endoh, 1991; Proven et al., 2006) and unlike the situa-
tion in the atria, a negative inotropic response is rarely
observed (Proven et al., 2006). Notably, ET-1 also affects heart
rate by modulating the physiology of the SA node and
Purkinje fibres (Ishikawa et al., 1988a). The combined effect
of ET-1-induced positive inotropy and chronotropy increases
cardiac output under conditions of stress, contributing to the
adaptive response of the heart. However, these actions of ET-1
also have deleterious consequences, promoting arrhyth-
mogenic, action potential-independent calcium transients
(Baltogiannis et al., 2005; Li et al., 2005; Mayyas et al., 2010).
Similarly to other cardiotonic agonists, ET-1 changes
cardiac contractility by modulating components of the ECC
machinery (Figure 3). These include alterations in the
dynamics and amplitude of systolic calcium transients
(Bootman et al., 2007; Kockskamper et al., 2008), changes in
myofilament sensitivity to calcium (Yang et al., 1999; Westfall
et al., 2005; Cuello et al., 2007a) or altered frequency of
stimulation (Ishikawa et al., 1988a).
ET-1 regulation of NCX activity
ET-1 effects systolic calcium predominantly via modulation
of the Na+/Ca2+ exchanger (NCX) (Ballard and Schaffer, 1996;
Yang et al., 1999) and L-type channel activity (Ono et al.,
1994). The primary function of NCX is calcium clearance
from the cytosol during diastole, accounting for up to 20% of
the calcium extruded, a contribution that increases further
under disease conditions (Bers, 2002; 2006). NCX uses the
electrochemical gradient for Na+ between the extracellular
space and the cytosol, created by the Na+K+-ATPase, to
exchange 3 Na+ for every calcium ion extruded from the cell
(Philipson and Nicoll, 2000). Where intracellular calcium is
increased independently of an action potential, NCX-
mediated Na+ entry may cause sufficient depolarization to
cross the threshold for action potential generation (Gilbert
et al., 1991). As well as this forward mode of activity, NCX can
also operate in reverse, inducing calcium influx (Leblanc and
Hume, 1990). This may be precipitated by raised intracellular
Na+ concentration under conditions of membrane depolari-
zation, for example during the initial phase of the action
potential (Shattock and Bers, 1989). As a result of calcium
influx at this point, calcium transients are increased in ampli-
tude and contractility enhanced (Meyer et al., 1996; Yang
et al., 1999). ET-1 regulates NCX either by engaging signalling
mediators activated directly downstream of the ETA receptor
such as PKC (Ballard and Schaffer, 1996; Zhang and Hancox,
2009), or by increasing activity of the sodium-hydrogen
exchanger (NHE) (Cingolani et al., 2011). The NHE is the
major mechanism by which intracellular pH is regulated in
cardiac myocytes. It extrudes one H+ ion from the cell in
exchange for 1 Na+ (Cingolani and Ennis, 2007), exploiting
the Na+ gradient created by the Na+K+-ATPase. The resulting
increase in intracellular Na+ activates NCX in reverse mode,
increasing [Ca2+]i and producing an inotropic effect (Alvarez
et al., 1999). H+ extrusion by NHE would also be expected to
modulate contractility via cytosolic alkalanization, which
Figure 2
Excitation–contraction coupling in the cardiomyocyte. Opening of voltage-gated Na+-channels induces cellular depolarization (1). L-type
voltage-gated calcium channels are activated in response to depolarization and mediate calcium entry (2). Increased calcium concentration within
the cardiac dyad activates the closely opposed RyR2 and induces calcium-induced-calcium release (3), raising cytosolic calcium concentration.
Calcium diffuses to the contractile apparatus (4), binds to the contractile filaments and stimulates contraction (5). Calcium is re-sequestered in
the sarcoplasmic reticulum or extruded from the cell by NCX, returning cytosolic calcium concentration to resting levels (6). Colocalization of IP3RII
within the cardiac dyad facilitates calcium-induced calcium release under stimulated conditions.
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would influence myofilament calcium sensitivity. Despite
support for this hypothesis in earlier studies, it is now clear
that the small changes in intracellular [H]i produced by NHE
are compensated for by the bicarbonate anion transporter;
providing bicarbonate is present in the extracellular medium
(Alvarez et al., 1999). Therefore, this mechanism is unlikely to
contribute to the ET-1 response. ET-1 increases NHE activity
via kinases such as PKC, ERK1/2 and p90 RSK (Bianchini et al.,
1997; Fliegel and Karmazyn, 2004; Maekawa et al., 2006;
Cuello et al., 2007b; Snabaitis et al., 2008). Although ERK1/2
and therefore p90 RSK may both be activated via canonical
GPCR signalling, NADPH oxidase activation and ROS forma-
tion are necessary for these kinases to phosphorylate NHE in
response to ET-1 (Cingolani et al., 2011).
ET-1 regulation of L-type
calcium current
L-type calcium channel activity is subject to extensive regu-
lation by GPCRs, which elicit their effects through PKC and
PKA dependent phosphorylation (Puri et al., 1997; Kamp
and Hell, 2000). Phosphorylation of the pore-forming a1C
and accessory a1s and b2a subunits of the channel has been
detected biochemically (Puri et al., 1997). Although inten-
sively studied, there is a lack of consensus regarding modu-
lation of L-type calcium current (ICa,L) by ET-1, with evidence
for both a positive (Lauer et al., 1992; He et al., 2000) and
negative effect (Ono et al., 1994; 2001; Cheng et al., 1995). A
biphasic effect of ET-1 has been reported in rabbit ventricular
myocytes, consisting of a reduction followed by an enhance-
ment of ICa,L (Watanabe and Endoh, 1999). In these cells the
ET-1 stimulated augmentation of ICa,L approached a level
similar to that induced by b-adrenoreceptor stimulation.
However, the mechanisms by which ET-1 and sympathetic
stimuli affect ICa,L are not shared. When ET-1 and sympathetic
stimuli occur concurrently, ET-1 exerts an anti-adrenergic
effect through a pertussis toxin-sensitive pathway (i.e. Gi/o
mediated). This suppresses the enhancement of ICa,L by
b-agonists and prevents their associated inotropic (Boixel
et al., 2001; Munzel et al., 2005) and arrhythmic responses
(Kolettis et al., 2008). In addition to the inter-species varia-
tion in the ET-1 response, the lack of a consistent effect of
ET-1 has also been ascribed to the methods used for recording
ICa,L (He et al., 2000). In order to mitigate this, the perforated
patch technique has been used to minimize intracellular
dialysis and loss of signalling mediators. Using this approach,
a consistent PKC-dependent positive regulation of ICa,L by
ET-1 has been reported (Kamp and Hell, 2000). In order for
such a mechanism to operate efficiently, co-localization of
the main players is required to facilitate interaction of the
DAG generated by phosphoinositide hydrolysis with its
targets (Robu et al., 2003). The importance of DAG localiza-
tion is illustrated by the contrasting effects of bath-applied
and intracellular-released DiC8, a DAG analogue (He et al.,
Figure 3
ET-1 regulates ventricular myocyte contractility. Downstream of the ETA receptor in the ventricular myocyte, IICR, PKC, PKD, p90 RSK and ERK are
activated. Protein-kinase-dependent phosphorylation of NHE1 increases intracellular Na+ concentration and depolarizes the cell. Subsequent
activation of NCX in reverse mode allows calcium entry to be enhanced. When combined with PKC-dependent amplification of calcium entry
through the L-type calcium channel, the stimulus for CICR is increased. IP3-dependent calcium release from the SR sensitizes the closely opposed
RyR2, hence facilitating CICR. The resulting elevated cytosolic calcium concentration and PKC/PKD-dependent phosphorylation of myofilament
proteins allows the myocyte to produce a larger force of contraction.
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2000). Bath application of DiC8 induces a PKC-independent
reduction in ICa,L whereas intracellular photoactivation of
caged DiC8 mimics the PKC-dependent enhancement of ICa,L
observed with ET-1 application (He et al., 2000). Although
PKC phosphorylates and activates L-type channels directly,
the effects of PKC activation could also be transduced by
calcium/calmodulin-dependent protein kinase II (Komukai
et al., 2010). Furthermore, ET receptors, PLCb and PKCe are
all localized to the sarcolemma of the t-tubule in ventricular
myocytes, bringing them into close proximity with L-type
calcium channels (Robu et al., 2003). Interestingly, in disease
situations where t-tubules are lost, ET-1 no longer elicits a
positive inotropic effect (Chung et al., 2008; Smyrnias et al.,
2010).
ET-1 stimulated IP3-induced calcium
release and cardiac contractility
As well as DAG, ET-1-dependent phosphoinositide hydrolysis
in the myocytes and conduction system of the heart gener-
ates the important signalling effector IP3 (Chen et al., 2004;
Remus et al., 2006; Hirose et al., 2008; Kockskämper et al.,
2008b; Ju et al., 2011). Due to the relatively small increase in
IP3 and low expression level of IP3 receptors (IP3Rs) in heart
preparations relative to other tissues, the role, if any for IP3 in
modulating intracellular [Ca2+] and contractility was for a
long time unclear (Wu et al., 2006; Higazi et al., 2009). Fur-
thermore, since expression of IP3Rs is 50–100 fold lower than
that of the RyR (Moschella and Marks, 1993; Perez et al.,
1997; Lipp et al., 2000), it was difficult to discern what addi-
tional function IP3Rs could perform. This contrasts with the
prominent role for IP3Rs in the development and physiology
of the embryonic heart. Indeed, mice in which the type 1 and
type 2 IP3R isoforms (IP3RI and IP3RII) are subject to germ-line
deletion are not viable and exhibit defects in cardiac devel-
opment (Uchida et al., 2010). Moreover, IP3 stimulated
calcium signals play a key role in pacemaker activity of the
embryonic heart (Kapur and Banach, 2007). Evidence has
recently accumulated which indicates that despite low
expression of IP3Rs, the IP3 signalling pathway also plays a
significant role in the physiology and pathophysiology of the
adult heart, contributing to many of the effects of ET-1 and
other Gaq coupled receptors on cardiac function (Wu et al.,
2006; Kockskämper et al., 2008b; Higazi et al., 2009;
Nakayama et al., 2010). As would be expected, the contribu-
tion of IP3 signalling to the action of ET-1 across the regions
of the heart varies according to the level of expression and
subcellular localization of the IP3R. Similarly to ETA receptors,
IP3Rs are most abundant in atrial myocytes and in nodal
tissue (Lipp et al., 2000; Ju et al., 2011). The IP3RII predomi-
nates in SA node, atrial and ventricular myocytes (Perez et al.,
1997; Lipp et al., 2000; Ju et al., 2011), whereas in Purkinje
fibres, IP3RI is most abundant (Gorza et al., 1993).
Engagement of IP3 signalling in the different cell types of
the heart has varying consequences. In the SA node, ET-1
causes increases in firing rate, calcium transient amplitude,
diastolic calcium levels and the frequency of elementary
calcium release events (Ju et al., 2011). The recapitulation of
these effects by exposure of nodal cells to cell-permeant IP3
and the decreased firing rate and loss of ET-1 responses in
nodal cells from IP3R knockout mice demonstrates the impor-
tance of ET-1/IP3 signalling in this region of the heart (Ju
et al., 2011). Although ET-1 also elicits a positive chrono-
tropic effect in guinea pig SAN (Ishikawa et al., 1988a), rabbit
SAN exhibits a negative chronotropic response to ET-1 (Ono
et al., 2001). The effect of ET-1 in these rabbit cells was attrib-
uted to modification of calcium and potassium currents. The
role of IP3 signalling in eliciting the effects of ET-1 upon the
SAN in species other than mouse remains to be fully resolved.
ET-1 also elicits spontaneous events in Purkinje fibres. Despite
evidence for expression of functional IP3Rs that contribute to
spontaneous calcium release events in these cells (Gorza
et al., 1993; Wu and Tseng, 1993; Boyden et al., 2004), it is not
determined whether these IP3Rs are engaged by ET-1 (Wu and
Tseng, 1993). The IP3R is however stimulated in Purkinje cells
by IP3 generated following activation of a-adrenergic GPCRs,
resulting in wide long lasting calcium release events (Hirose
et al., 2008).
In atrial myocytes, IP3 signalling contributes to the ino-
tropic and pro-arrhythmic action of ET-1 (Li et al., 2005), and
IP3-mediated calcium signals are localized to the sub-
sarcolemmal and perinuclear regions (Mackenzie et al., 2004;
Zima et al., 2007). Whilst perinuclear IP3-mediated calcium
signals have been proposed to control transcription (see later)
(Wu et al., 2006; Higazi et al., 2009), IP3-mediated calcium
signals at the plasma membrane play a role in modulating
atrial myocyte contractility and may underlie the enhanced
automaticity of ET-1 stimulated myocytes (Mackenzie et al.,
2004). A similar pattern of IP3R expression and activity is
observed in cells of the SAN (Ju et al., 2011). As a result of
their lack of t-tubules, ECC is restricted to the peripheral
sarcolemma of atrial myocytes (Ju et al., 2011). Therefore,
IP3-mediated calcium signals exert a greater than anticipated
effect on the physiology of an ET-1-stimulated atrial or SAN
myocyte due to their co-localization with the ECCmachinery
in these cells. ET-1-stimulated IP3-mediated calcium signals
promote transition of the sub-sarcolemmal ring of calcium
normally observed following depolarization of atrial myo-
cytes to a global calcium elevation, enhancing ECC and
recruitment of RyRs deeper in the myocyte cell volume (Mac-
kenzie et al., 2004). As a result, contractility is increased and
blood propelled with greater force into the ventricles. Since
the extent of ventricular stretch determines the contractile
force produced by the ventricle – the Frank Starling relation-
ship – greater atrial contraction brings about increased
cardiac output. In addition to enhancing electrically evoked
calcium transients, ET-1 application also increases the inci-
dence of elementary calcium release events in atrial myocytes
(Mackenzie et al., 2001; Li et al., 2005). These events contrib-
ute to an increase in diastolic calcium levels beneath the
sarcolemma, which if sufficiently elevated, activates NCX-
dependent inward Na+ flux and action potential generation.
As a result, a potentially arrhythmogenic ectopic event is
induced (Lipp et al., 2000; Mackenzie et al., 2002).
Functional interactions between IP3Rs and RyRs are also
observed in ventricular myocytes exposed to ET-1 (Proven
et al., 2006; Domeier et al., 2008; Harzheim et al., 2009).
However due to the lower abundance of ET and IP3 receptors
in these cells (Lipp et al., 2000; Domeier et al., 2008), their
interaction and influence upon myocyte physiology is not as
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great. Most notably, IP3 signalling does not make a prominent
contribution to the inotropic action of ET-1 in the ventricular
myocyte. This is not surprising given the limited effect of ET-1
upon calcium fluxes in these cells when compared with atrial
myocytes (Proven et al., 2006; Domeier et al., 2008). Pro-
longed exposure of ventricular myocytes to ET-1 does
however lead to the generation of ectopic calcium transients
and IP3-dependent extra-systolic contractions (Proven et al.,
2006) and IP3-dependent calcium signals also promote
sodium-calcium exchange (Gilbert et al., 1991). Thus, simi-
larly to the situation in atrial myocytes, ET-1 activated IP3
signalling has the potential to precipitate ventricular
arrhythmias.
As discussed earlier, both circulating and local cardiac
ET-1 levels are increased with age (Maeda et al., 2003) and
during cardiac pathologies such as arrhythmia, infarction
and hypertrophy (Yorikane et al., 1993; Serneri et al., 2000).
Although this increase in ET-1 may initially support ECC, it
also has deleterious consequences and is likely to exacerbate
pathology and/or cause it to persist (Tuinenburg et al., 1998;
Baltogiannis et al., 2005; Mayyas et al., 2010). Furthermore,
IP3Rs are increased in their abundance during cardiac pathol-
ogy (Moschella and Marks, 1993; Harzheim et al., 2009;
2010). As a result, the effects of ET-1 on myocyte physiology
are enhanced. Notably, the additional IP3Rs in the hypertro-
phied heart are not homogenously distributed throughout
the cell volume but localized to the sub-sarcolemmal dyadic
region, proximal to the RyRs that participate in ECC
(Harzheim et al., 2009). Thus, under conditions of increased
IP3, calcium emanating from these IP3Rs stimulates calcium
release from their neighbouring RyRs. The effects of this
activity are twofold. First, IICR may promote ECC, thereby
enhancing contractility. However, second, IICR may promote
potentially arrhythmogenic ectopic calcium release events
(Harzheim et al., 2009). On balance, the enhancement of
calcium release via RyRs by the additional IP3Rs may out-
weigh the potential deleterious effects of ectopic calcium
signals. During hypertrophy and the progression to failure,
decreased coupling efficiency between L-type channels and
RyRs arises as a result of increased width of the dyadic cleft
(Song et al., 2006; Xu et al., 2007; Heinzel et al., 2011). In this
situation, calcium release through additional IP3Rs could
provide a mechanism to overcome this defect in ECC by
bringing RyRs closer to their threshold for activation. This
effect is analogous to the priming of RyRs by PKA phospho-
rylation following b-stimulation, which sensitizes the recep-
tors to calcium influx via LTCC (Zhou et al., 2009). In this
way, increased IP3R expression may be considered an adaptive
response that sustains contractile function as the heart
hypertrophies.
Effects of ET-1 upon the
contractile apparatus
The relationship between the enhancement in [Ca2+]i and
contractility observed in cardiac preparations following expo-
sure to ET is non-linear, indicating that the inotropic
response does not solely result from enhancement of intrac-
ellular calcium levels. This non-linearity is particularly appar-
ent in ventricular preparations where, despite a significant
increase in contraction, [Ca2+]i is not substantially augmented
(Wang et al., 1991; Pieske et al., 1997). This contrasts with the
response to the catecholamines, which cause a robust
increase in calcium transient amplitude and contractility. The
mechanism by which the alteration in contraction is brought
about by catecholamines is well defined and occurs primarily
through PKA-dependent phosphorylation of contractile fila-
ment regulatory proteins, most notably the inhibitory
subunit of troponin (TnI) and myosin binding protein C
(MyBP-C) (Chen et al., 2010). Phosphorylation of TnI and
MyBP-C differentially contributes to regulation of contractil-
ity. Phosphorylation of TnI reduces calcium sensitivity of the
myofilaments (Pi et al., 2003), and phosphorylation of
MyBP-C is responsible for enhanced cross-bridge cycling,
thereby enhancing relaxation (Chen et al., 2010). GPCRs that
signal via Gaq such as the ETA receptor elicit an opposing
effect on myofilament action – generally increasing sensitiv-
ity to calcium and decreasing cross-bridge cycling (Pi et al.,
2003; Wang et al., 2006). As such, their modulation of con-
tractility is energetically less expensive. PKC, RSK and PKD
have all been identified as ET-1-activated TnI and MyBP-C
kinases (Cuello et al., 2007a; 2011; Chen et al., 2010).
Remodelling of the heart by ET-1
In addition to its diverse actions in the regulation of myocyte
contractility, ET-1 has been consistently demonstrated to
perform a major role in disease-associated remodelling of the
heart (Russell and Molenaar, 2000; Sugden, 2003). Heart
disease encompasses a spectrum of interrelated and progres-
sive disorders, which include hypertension, coronary artery
disease, arrhythmia and, most severely, heart failure (Diwan
and Dorn, 2007). Pathological enlargement of the heart,
termed maladaptive cardiac hypertrophy, is observed clini-
cally in many of these conditions and can be induced as a
result of increased arterial blood pressure, genetic mutations
or following myocardial injury. Hypertrophic remodelling
can take place within the left and/or right ventricles, depend-
ing on the nature of the initiating stimulus. It develops as a
consequence of the increased size of individual ventricular
myocytes, without an increase in myocyte number. When
hypertrophy occurs as a consequence of persistent cardiovas-
cular stress, an increase in heart size is a pathological and
maladaptive response. As the condition progresses to heart
failure, myocyte apoptosis/necrosis and myocardial fibrosis
are observed, impairing cardiac contractility and reducing
cardiac output. At the cellular level, hypertrophic myocytes
show remodelling of gene expression profiles, altered intrac-
ellular calcium handling and reorganization of the contrac-
tile machinery. Reprogramming of cardiomyocyte gene
expression profiles is responsible for many of the phenotypic
changes observed in hypertrophic myocytes and is perceived
to be critical for disease-associated impairment of myocyte
function. Left ventricular hypertrophy produced by repro-
gramming under pathological conditions is one of the major
risk factors for subsequent progression of patients to conges-
tive heart failure and sudden death (Jessup and Brozena,
2003), prompting much investigation into the mechanism of
action of pro-hypertrophic stimuli. Exposure of cultured car-
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diomyocytes to ET-1 has been shown to recapitulate many of
the cellular features of hypertrophic myocytes (Ito et al.,
1991). Furthermore, ET-1 stimulation of NRVM alters expres-
sion of hundreds of genes, in a manner mirroring the remod-
elling of gene expression observed during hypertrophy
(Cullingford et al., 2008). Consequently, these observations
have promoted much investigation into the role of the ET-1
system in pathological remodelling.
As indicated earlier, cardiomyocyte ET-1 biosynthesis and
secretion and ET receptor expression are increased in heart
failure patients and animal models of cardiovascular condi-
tions (Hasegawa et al., 1996; Motte et al., 2003; McMullen
and Jennings, 2007). This remodelling of the ET system
thereby provides a local mechanism for the pathological
effects of ET-1. The importance of a local role for ET-1 in the
induction of myocardial remodelling has been demonstrated
by the effects observed upon infection of an organism with
the intracellular protozoan Trypanosoma cruzi. Parasite infec-
tion leads to the development of Chagas disease (Coura and
Viñas, 2010), which in its chronic form induces a cardiomyo-
pathic phenotype, consisting of cardiomyocyte hypertrophy,
myocardial fibrosis and, eventually, myocyte death. Together,
these changes promote the development of heart failure
(Coura and Borges-Pereira, 2010). Similar to other forms of
hypertrophic remodelling, plasma ET-1 concentration is high
in mice and humans infected with T. cruzi and mRNA levels
of both ET-1 itself and the enzymes involved in its processing
are increased under these conditions (Petkova et al., 2000;
Salomone et al., 2001). When the ET-1 gene is specifically
deleted in cardiomyocytes, the maladaptive effects of T. cruzi
infection are reduced. Such a protective effect is not observed
upon deletion of ET-1 in endothelial cells, suggesting a
myocyte-specific ET-1-dependent origin for the cardiomyo-
pathic effect of the disease (Tanowitz et al., 2005).
Manipulation of the ET-1 system experimentally in
murine models of hypertrophy and heart failure has provided
valuable further insight into the role of the peptide in left
ventricular remodelling. Cardio-specific conditional overex-
pression of ET-1 in mice induces a pathological hypertrophic
phenotype, which can be attenuated by combined blockade
of ETA and ETB receptors (Yang et al., 2004), whilst cardio-
specific deletion of the ET-1 gene inhibits the hypertrophic
response to treatment with the T3 thyroid hormone (Shohet
et al., 2004). Infusion of the ETA receptor antagonist, BQ123,
inhibits the response to a pro-hypertrophic stimulus in adult
rats (Ito et al., 1994) and when administered to rats experi-
encing chronic heart failure, BQ123 impedes left ventricular
remodelling and improves survival (Sakai et al., 1996). These
observations support the conclusion that ET-1 and the ETA
receptor have an important role in pathological remodelling
of the heart.
Based on these findings, the signalling pathways activated
downstream of ET-1 and ETA receptor activation have been
extensively studied within the context of the hypertrophic
response. Overexpression of PLCb1b, a primary proximal
target of the ETA receptor, is sufficient to induce a hyper-
trophic response in NRVM (Filtz et al., 2009). Moreover, by
inducing calcium signals and activation of PKC, respectively,
the IP3 and DAG generated following ET-1 stimulated
PLC-mediated phosphoinositide hydrolysis have pro-
hypertrophic effects.
Role of IP3-dependent calcium release
in hypertrophy
The low baseline expression of the IP3RII in ventricular myo-
cytes (Perez et al., 1997) has impeded investigation into its
role in hypertrophic remodelling. Moreover, it has been
unclear how IICR arising from the relatively few cardiomyo-
cyte IP3RII could be discriminated from the cyclical global
release and reuptake of calcium that mediates cellular
contractility. However, it has been recognized that IP3RII
expression increases during cardiovascular disease, with
increased receptor expression being observed in human car-
diomyopathic hearts and animal models of hypertrophic
remodelling (Go et al., 1995; Harzheim et al., 2009; 2010;
Nakayama et al., 2010). As well as being expressed in the
dyadic region, these receptors are also found in the peri-
nuclear region. IP3-dependent nuclear calcium signals occur
in response to ET-1 and are required to elicit a hypertrophic
response (Wu et al., 2006; Higazi et al., 2009). Furthermore, a
mouse-model with cardio-specific overexpression of the
IP3RII demonstrated enhanced IP3-induced calcium release
(IICR) and mild baseline hypertrophy (Nakayama et al.,
2010). Together, these data suggest that IICR has a pro-
hypertrophic effect on the myocardium and that nuclear
IICR plays a key role in the hypertrophic response to ET-1.
The observation that ET-1 elicits release of calcium specifi-
cally in the nuclear domain is significant as it would allow
pro-hypertrophic IP3-dependent calcium signals to be
detected independently from the bulk calcium transients
that elicit myocyte contractility. Furthermore, calcium eleva-
tion within the nucleus co-localizes the calcium signal with
calcium-sensitive kinases and regulators of transcription, spa-
tially coupling the stimulus with its effectors (Goonasekera
and Molkentin, 2012). Such mechanisms are likely to be
crucial for the remodelling of gene expression profiles
observed in hypertrophy. Calcineurin-nuclear factor of acti-
vated T cells (Cn-NFAT) (Higazi et al., 2009; Nakayama et al.,
2010; Rinne and Blatter, 2010) and CaMKII (Wu et al., 2006),
are examples of IICR-regulated proteins that can be localized
within the nucleus. Significantly, both have important roles
in the hypertrophic response.
Calcineurin (Cn) is a calcium-dependent heterotrimeric
serine–threonine phosphatase (Clipstone and Crabtree, 1992;
Fruman et al., 1992). In response to increases in calcium con-
centration such as those elicited by ET-1-induced IP3 genera-
tion, IP3, the Cn autoinhibitory domain is displaced from the
active site, stimulating Cn phosphatase activity. The major
cellular target of activated Cn is a family of 4 Rel-homology
domain containing transcription factors, NFATc1-4 (Jain
et al., 1993). Subcellular localization of NFATc1-4 is control-
led by the phosphorylation status of the protein. Phosphor-
ylated NFAT is predominantly localized in the cytosol. When
Cn is active, NFAT is dephosphorylated, exposing two nuclear
localization sequences (NLS) and inducing translocation to
the nucleus, where it can activate transcription (Shaw et al.,
1995). Phosphorylation of NFAT by protein kinases such as
GSK3b (Neal and Clipstone, 2001), DYRK1a (Kuhn et al.,
2009), p38-MAPK (Gomez del Arco et al., 2000) and JNK
(Chow et al., 1997) leads to nuclear export of the protein
(Hogan et al., 2003). In response to ET-1 stimulation, multiple
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NFAT isoforms have been shown to translocate to the nucleus
of cultured cardiomyocytes (Kakita et al., 2001; Kawamura
et al., 2004; Higazi et al., 2009), with identity of the ET-1-
regulated isoforms species and cell-type specific (Rinne et al.,
2010). Interestingly, nuclear import of Cn has also been
observed in the cardiomyocyte, promoting sustained NFAT
dephosphorylation and prolonging the NFAT-signal (Shiba-
saki et al., 1996). Indeed, nuclear translocation of Cn is
required for the response to ET-1 in NRVM (Hallhuber et al.,
2006; Higazi et al., 2009).
Cn-NFAT activity within the cardiomyocyte is undoubt-
edly important for the hypertrophic effects of ET-1, and there
is a wealth of further evidence that convincingly demon-
strates the pathological role of Cn-NFAT activity within the
heart. Failing human myocardium exhibits increased expres-
sion and activity of Cn and translocation of NFATc4 to the
nuclear compartment (Lim and Molkentin, 1999; Diedrichs
et al., 2004). These observations have been further substanti-
ated by in vitro and in vivo studies. Overexpression of a
constitutively-active mutant of Cn in the mouse heart
induces severe left ventricular hypertrophy, cardiomyocyte
dysfunction and heart failure (Molkentin et al., 1998). To
further confirm these conclusions, other studies have probed
the role of Cn-NFAT downstream of hypertrophic stimuli
such as ET-1 in vitro. ET-1 increases Cn enzymatic activity in
NRVM, inhibition of which prevents the response to hyper-
trophic stimulation (Zhu et al., 2000). Moreover, multiple
studies have verified that the deleterious effect of Cn on
cardiac function is mediated through Cn-dependent regula-
tion of one or more NFAT isoforms. Constitutively nuclear,
constitutively active NFATc4 induces a phenotype of patho-
logical left ventricular hypertrophy, confirming the damag-
ing effect of increased NFAT-transcriptional activity in vivo
(Molkentin et al., 1998). Moreover, cardio-specific deletion of
either NFATc3 (Wilkins et al., 2002) or NFATc2 (Bourajjaj
et al., 2008) impairs the hypertrophic response to increased
Cn activity. Although these mouse models do not directly
interrogate the role of ET-1-induced Cn-NFAT activity during
hypertrophy, when combined with the evidence for ET-1-
dependent NFAT translocation in isolated myocytes and the
requirement for Cn in the hypertrophic response to ET-1, this
pathway can be considered to be an important mediator of
ET-1 induced hypertrophic responses.
Signalling to CaMKII, HDACs and
MEF2 to induce hypertrophy
Although Cn-NFAT are strongly implicated in the hyper-
trophic response to ET-1, other studies have shown that ET-1-
induced nuclear IICR elicits its pro-hypertrophic effect by
engaging co-localized CaMKII and eliciting gene expression
dependent upon the pro-hypertrophic transcription factor
MEF2 (Wu et al., 2006). Basally, MEF2 activity is restrained in
the myocyte as a consequence of its association with class II
histone deacetylases (HDACs 4,5,7 and 9), which negatively
regulate transcription by deacetylating histone proteins,
resulting in condensation of chromatin and impeding the
access of transcriptional activators. In response to peri-
nuclear IICR, CaMKII phosphorylates HDAC4 creating a
docking site for 14-3-3 proteins. Association of HDAC4 with
14-3-3 induces conformational changes that mask NLS and
expose a nuclear export sequence, facilitating HDAC4 nuclear
export and depressing MEF2-dependent transcriptional
responses (Lu et al., 2000; Zhang et al., 2002; Wu et al., 2006).
ET-1 induces nuclear export of both HDAC4 and HDAC5 in
rat ventricular myocytes (Wu et al., 2006; Peng et al., 2009),
and ET-1 induced activation of MEF2-dependent trans-
cription is likely to form a key component of the cellular
response to the peptide. Deletion of MEF2D abrogates the
hypertrophic response induced by hypertension-induced
hypertrophy (Chang et al., 2004; Kim et al., 2008), whilst
overexpression of MEF2A, C or D in vivo is sufficient to induce
pathological cardiac remodelling (Kim et al., 2008).
Recent reports indicate that the spatial pattern of ET-1-
induced signalling is important in the regulation of HDAC
phosphorylation. ET-1 activates CaMKII kinase activity, and
this activity is necessary for the hypertrophic response to the
peptide in NRVM (Zhu et al., 2000). CaMKII itself is a key
inducer of HDAC nuclear export, with cardiomyocytes pre-
dominantly expressing the CaMKIId isoform, localized to
either the nucleus (CaMKIIdB) or cytosol (CaMKIIdC) (Ander-
son, 2005). CaMKIIdB is therefore present in the vicinity of its
activating signal (ET-1-induced nuclear calcium transients)
and its target (HDAC4). Although CaMKII directly targets
HDAC4, it does not directly phosphorylate HDAC5. HDAC5
is rendered sensitive to CaMKII by forming oligomers with
HDAC4 (Backs et al., 2008), indicating that ET-1-induced IICR
could lead to nuclear export of both of the key MEF2 repres-
sors. More recently, the novel calcium independent isoforms
of PKC and the PKC target PKD have also been shown to
phosphorylate HDAC5 and induce its nuclear export (Phan
et al., 2011). ET-1 activates both PKC and PKD in cardiomyo-
cytes (Phan et al., 2011); however, this is unlikely to form part
of the mechanism whereby ET-1 depresses MEF2. ET-1-
induced HDAC5 nuclear export is PKC-independent and
although ET-1 activates subsarcolemmal PKD, it does not
stimulate PKD translocation to the nucleus, preventing access
of the kinase to its nuclear targets (Bossuyt et al., 2011).
Therefore, peri-nuclear IICR and the CaMKII activity it elicits
are considered to be the key signals for ET-1-induced MEF2
depression.
ET-1 activation of PKC in hypertrophy
ET-1 activates the novel isoforms of PKC in cardiomyocytes.
PKC isoform expression is species, tissue and cell-type-
specific, with cardiomyocytes from murine species and
humans expressing multiple differentially regulated PKC
isoenzymes (Salazar et al., 2007; Palaniyandi et al., 2009).
NRVM express PKCs a, d, e and h (Clerk et al., 1995; Erdbrug-
ger et al., 1997; Markou et al., 2006), whilst human cardiac
tissue also expresses PKC bI and bII (Bowling et al., 1999). In
NRVM, ET-1 induces membrane association and activation of
the DAG-sensitive, calcium-insensitive PKC d and e isoforms
within 5 min of stimulation (Clerk et al., 1994; Clerk and
Sugden, 1997), and PKC e is the major ET-1-activated isoform
in AVM (Bogoyevitch et al., 1993). The role of PKC isoen-
zymes in hypertrophy has been intensively investigated (Braz
et al., 2002; Vega et al., 2004; Vijayan et al., 2004). This has
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lead to the identification of many downstream targets of PKC
relevant to hypertrophy in cardiomyocytes, such as the small
G-protein Ras (Montessuit and Thorburn, 1999), mTOR,
ribosomal S6 kinase (Moschella et al., 2007), GSK3b (Zhai
et al., 2007), GATA4 (Wang et al., 2005) and PKD (Vega et al.,
2004). Although PKC regulates multiple targets, activation of
Ras and downstream MAPK cascades by the DAG-sensitive
isoforms of PKC is considered to have a predominant role in
cardiac remodelling (Braz et al., 2002).
MAPK signalling pathways in the
hypertrophic response
Upon ET-1 binding to the ETA receptor, the classical small g
protein Ras is converted into an active, GTP-bound form.
Multiple mechanisms have been suggested to explain this
effect, relying on the activity of PKC as described above
and/or ET-1-induced production of intracellular reactive
oxygen species (ROS) (Sugden and Clerk, 2006). Clinically,
activating mutations in Ras and its target Raf result in Cos-
tello and Noonen syndromes respectively, both of which
induce cardiomyopathy amongst other abnormalities (Lin
et al., 2011; Wu et al., 2011). Induction of hypertrophy by
activated Ras and Raf is ERK1/2 dependent, suggesting that
this kinase is responsible for the hypertrophic response to Ras
and Raf activation (Harris et al., 2004; Wu et al., 2011).
However, although it has been intensively investigated, the
precise role and function of activated ERK1/2 in the heart
remains controversial (Bueno and Molkentin, 2002; Kehat
and Molkentin, 2010). It has been appreciated for many years
that ERK1/2 is activated in NRVM in response to hyper-
trophic agonists including ET-1 (Bogoyevitch et al., 1994).
Moreover, inhibition of ERK1/2 activation using either phar-
macological inhibitors of its activating kinases MEK1/2 or
adenoviral-mediated overexpression of dominant-negative
MEK prevents the hypertrophic response to ET-1 in NRVM
(Ueyama et al., 2000; Yue et al., 2000). Indeed, microarray
studies demonstrated the reliance of ET-1-induced hyper-
trophic gene expression on ERK1/2 activity (Marshall et al.,
2010). However, these observations have been called into
question following in vivo studies of transgenic mouse
models. Cardiac-specific overexpression of constitutively-
active MEK1 induces ERK1/2 phosphorylation and compen-
sated concentric hypertrophy (Bueno et al., 2000). Therefore,
activation of ERK1/2 above the baseline level, as occurs in
vitro in response to ET-1, can induce cardiac remodelling.
However, in vivo loss-of-function studies of ERK1/2 have dem-
onstrated that under certain conditions the hypertrophic
response is preserved, calling into question the necessity of
these kinases during pathology. Echoing the current thinking
regarding calcium-regulated signalling, interesting observa-
tions suggest that spatial and contextual aspects of ERK1/2
activation may govern whether it exhibits pro-hypertrophic
activity. Interestingly, in vascular smooth muscle cells and
fibroblasts, ET-1 induces nuclear translocation of ERK1/2
(Lenormand et al., 1993; El-Mowafy and White, 1999) where
it can phosphorylate targets involved in regulation of gene
transcription. These include transcription factors (e.g. GATA4
and Elk), nuclear kinases (e.g. MSK1) and chromatin modify-
ing enzymes (e.g. the p300 histone acetylase). In cardiomyo-
cytes, a novel phosphorylated form of ERK1/2 (p-Thr188-
ERK1/2) accumulates within the nucleus over the duration of
the hypertrophic response in vivo, an effect that could also be
simulated in vitro by agonists of Gaq-coupled receptors
(Lorenz et al., 2009). Hence, it is conceivable that ERK1/2
activity becomes more important in the later stages of hyper-
trophy, once sufficient nuclear accumulation has occurred.
Furthermore, the basal and stimulus-induced levels of ERK1/2
activity may have different functional effects within the
myocyte (Kehat et al., 2011). In the context of cellular stimu-
lation with agonists such as ET-1, mechanisms may be acti-
vated that permit ERK1/2 to perform functions other than
those active under non-stimulated conditions, changing the
cellular response to the kinase. Discriminating whether,
when and how ERK1/2 regulates hypertrophy is an interest-
ing topic of future research.
Although the requirement for ERK1/2 during remodelling
remains controversial, many of the targets of the kinase have
defined pro-hypertrophic roles. Genome-wide studies of
myocyte gene expression profiles have shown that ET-1
induces distinct waves of gene expression, with the earlier
phases of the response being largely ERK1/2 dependent (Cull-
ingford et al., 2008; Marshall et al., 2010). Demonstrating the
importance of these acute events, inhibiting activity of the
activator protein-1 (AP1) complex of the immediate-early
genes c-fos and c-jun prevents ET-1-induced hypertrophic
remodelling (Omura et al., 2002). Other transcription factors
also exhibit ET-1-induced ERK1/2-dependent activity. For
example, GATA4 shows ET-1-dependent DNA-binding activ-
ity in response to increased myocardial stretch (Hautala et al.,
2001; 2002; Liang et al., 2001) and is regulated by ERK1/2-
dependent phosphorylation (Liang et al., 2001). Expression
of GATA4 harbouring phospho-mimetic activating mutations
is pro-hypertrophic both in vitro and in vivo, whilst replacing
endogenous GATA4 with a mutant that cannot be phospho-
rylated on its activating sites impedes hypertrophic responses
(van Berlo et al., 2011). Interestingly, GATA4 can form higher
order complexes with other pro-hypertrophic transcription
factors such as NFAT and AP1, providing a mechanism
whereby pro-hypertrophic signalling pathways can be inte-
grated (Sanna et al., 2005).
Are JNK and p38-MAPK important for
ET-1-induced remodelling?
Early studies in NRVM demonstrated that both cellular
osmotic stress and ET-1 induce phosphorylation and activa-
tion of JNK1/2. However, the response to stress-associated
stimuli was much greater than the response to ETA receptor
activation. Subsequently, the role of JNK1/2 in hypertrophy
has been extensively examined. Overexpression of dominant-
negative MKK4, the kinase upstream of JNK1/2, attenuates
the hypertrophic response to ET-1 stimulation of NRVM
(Choukroun et al., 1998). These and other data suggest that
JNK1/2 mediates a pro-hypertrophic effect in vitro. However,
this observation has been questioned by other studies
showing that activation of JNK1/2 in vitro inhibits the hyper-
trophic response to ET-1 (Nemoto et al., 1998). To attempt to
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address the conflicting data sets, in vivo studies have been
performed. Currently, the prevailing consensus suggests that
although ectopic activation of JNK1/2 can induce cardiac
remodelling and eventual heart failure (Choukroun et al.,
1999), these changes occur in the absence of left ventricular
hypertrophy. Instead, myocardial stiffening has been
observed as a consequence of extracellular matrix remodel-
ling (Petrich et al., 2004). Intriguingly JNK1-/- knock-out mice
exhibited a hastened early deterioration in cardiac perform-
ance during hypertension-induced hypertrophy, suggesting
that the basal level of activity of this isoform may be impor-
tant for maintaining cardiac function (Tachibana et al.,
2006). The cardio-protective actions of JNK have been attrib-
uted to JNK-dependent phosphorylation and subsequent
nuclear export of the highly pro-hypertrophic transcription
factor NFAT (Chow et al., 1997) and/or JNK1/2-dependent
positive regulation of the anti-hypertrophic protein JunD.
The importance of JNK activity within the hypertrophic
response to ET-1 is likely to be governed by the balance of
stimuli within the ET-1-regulated signalling network.
Similarly to JNK, the exact role of p38-MAPK within the
myocardium has proven to be a matter for debate, with data
generated in vitro and in vivo producing somewhat conflicting
conclusions. Both ET-1 and cellular stress induce p38-MAPK
phosphorylation and activation. However, the kinase has
been demonstrated to either be necessary or dispensable for
the ET-1-induced hypertrophic response. Furthermore, the
different isoforms of p38-MAPK may have variable pathologi-
cal roles, with p38-MAPKa implicated in the induction of
apoptosis whilst p38-MAPKb is involved in hypertrophy. The
weight of evidence suggests that p38-MAPK activity is not
required for the initial development of left ventricular hyper-
trophy (Liao et al., 2001; Braz et al., 2003; Zhang et al., 2003;
Nishida et al., 2004). Indeed, akin to the action of JNK1/2,
p38-MAPK isoforms may be anti-hypertrophic as a conse-
quence of their NFAT-kinase activity during the early hyper-
trophic response (Gomez del Arco et al., 2000; Braz et al.,
2003). In the latter stages of cardiac decompensation and
heart failure, pathological functions for p38-MAPK have been
described. The kinase promotes ventricular dilation, stiffen-
ing and fibrosis thereby impairing contractility (Liao et al.,
2001; Zhang et al., 2003). Consequently, the effect of ET-1
stimulated p38-MAPK activity may not be important for the
initial response to the peptide, but become more significant
over time. A possible reason for this is that the remodelled
physiology and signalling pathways of the hypertrophic
heart creates a different profile of substrates or cellular
context for the action of p38-MAPK.
ET-1 signalling – a question of location
and timing?
When considered in their entirety, the importance of ET-1-
induced signalling pathways within the hypertrophic
response appears to be determined by two governing rules.
First, as described above, as a consequence of the remodelling
of gene expression that occurs during hypertrophy, the neces-
sity of the various ET-1-regulated mediators for the induction
of pathology may be altered over time. Secondly, subcellular
localization of ET-1-dependent signals is a critical determi-
nant of their pro-hypertrophic role. This is elegantly demon-
strated by the specific pro-hypertrophic effect of peri-nuclear
release of calcium in response to IP3RII activation. Interest-
ingly, the ETA receptor itself may also be subject to regulated
localization, a mechanism that could be important for its
cellular effects. The localization of GPCRs has been well
studied and several GPCRs are localized at the nuclear mem-
brane of cardiac myocytes and other cells types (Tadevosyan
et al., 2010; Vaniotis et al., 2011a; 2011b; Wright et al., 2012).
Although ETA receptors are largely found within the sarco-
lemma, several studies have demonstrated functional ETA
receptor and ETB receptor at the nuclear envelope of ventricu-
lar cardiomyocytes (Boivin et al., 2003; Bkaily et al., 2011).
This may result from translocation of ET receptors from the
cell surface or by de novo receptor synthesis. In order for
nuclear receptors to be functional, a source of intracellular
ligand must exist. It has been hypothesized that ET-1 pro-
duced intracellularly in the myocyte can signal in an intrac-
rine manner and that ET-1 is taken into the cell from an
extracellular source to act on nuclear ET receptors (Boivin
et al., 2003; Tadevosyan et al., 2012). Activation of nuclear
ETA receptor has been postulated to stimulate similar down-
stream pathways as sarcolemmal ETAR, such as PKC activation
and IP3 generation, thus potentially activating hypertrophic
gene expression and regulating calcium homeostasis (Bkaily
et al., 2011). As ET-1 production is increased in hypertrophic
and failing myocytes, under hypertrophic conditions, there
would be a larger stimulus to ET receptors located within the
cell. Furthermore, if present in the nucleus specifically, the
ETA receptor and the signalling pathways it initiates would
be clustered in close proximity of their cellular effectors,
facilitating ET-1-dependent cellular responses. Further studies
to substantiate the localization of ETA receptors within the
nucleus and their significance and relevance to the hyper-
trophic response are required to allow inclusion of sub-
cellular ET-1 signalling within the accepted models of ET-1
action.
Non-myocyte effects of ET in the heart
ET-1 signalling within the heart regulates a wide spectrum of
cardiovascular processes, ranging from development through
to life-threatening cardiovascular diseases. In this review, we
have focused upon ET signalling in cardiac myocytes. By
inducing the activity of a complex web of signalling path-
ways, this important peptide can directly influence myocyte
survival, contractility and remodelling. However, the heart is
composed of multiple cell types and despite providing the
greater part of cardiac mass, myocytes account for only ~20%
of the total number of cells in humans (Rubart and Field,
2006). The non-myocyte population is comprised of endothe-
lial cells, smooth muscle cells and fibroblasts (Nag, 1980;
Banerjee et al., 2007), all of which are responsive to ET-1
(Kedzierski and Yanagisawa, 2001). Cardiac endothelial and
smooth muscle cells form the myocardial vasculature. ET-1
interacts with these cells to regulate vascular tone, influenc-
ing myocardial blood supply and metabolic activity (Wang
et al., 1998). Cardiac fibroblasts are essential for secretion of
extracellular matrix and for cardiac repair (Biernacka and
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Frangogiannis, 2011). In response to elevated levels of ET-1,
cardiac fibroblasts proliferate, differentiate into myofibrob-
lasts and increase their secretion of matrix proteins (Shi-Wen
et al., 2004a; 2004b). These fibroblast responses underlie scar
formation following cardiac damage and the myocardium-
wide fibrosis associated with cardiac hypertrophy, where the
increased abundance of cardiac fibroblasts replaces the myo-
cytes lost as a result of pathology (Swynghedauw, 1999). The
reactive response of the fibroblast is essential for the mainte-
nance of cardiac function during disease, without which the
integrity of the heart is compromised (Shimazaki et al., 2008).
However, fibroblast infiltration alters the electrophysiological
properties of the myocardium, affecting both action potential
propagation and allowing arrhythmic events at the cellular
level to propagate (Mayyas et al., 2010; Karagueuzian, 2011).
Cardiac fibrosis also decreases elasticity of the heart, stiffen-
ing the myocardial wall and impeding cardiac output
(Lakatta and Levy, 2003a). Extensive fibrosis of the myocar-
dium is not only a characteristic of pathology but is also a
prominent feature of the aged, senescent heart and in
common with pathological situations, fibrosis of the aged
heart arises due to hypertrophy and myocyte loss (Lakatta
and Levy, 2003a; Biernacka and Frangogiannis, 2011). When
combined with the decreased relaxation rate of the aged
heart, these effects are manifest in diastolic dysfunction,
impacting exercise tolerance, quality of life and contributing
to future heart failure (Lakatta and Levy, 2003a). As ET-1
increases in concentration with age (Maeda et al., 2003) and
induces fibrosis (Shi-Wen et al., 2004a), the importance of the
ET-1 system for the decline in myocardial function associated
with age should be considered paramount.
Role of ET-1 in PAH and right
ventricular hypertrophy
The compelling evidence linking the ET-1 system to cardio-
vascular pathologies has prompted its targeting for therapeu-
tic benefit. Currently, the combined ETA-ETB receptor
antagonist bosentan and the selective ETA receptor antagonist
ambrisentan are licensed and successfully used for the treat-
ment of pulmonary arterial hypertension (PAH) (Kirkby et al.,
2008), a condition which induces right ventricular hypertro-
phy, right heart failure and eventually death (Gomberg-
Maitland et al., 2011). PAH increases pulmonary arterial
pressure and vascular resistance, stretching and increasing
the load on the right ventricle. Under these conditions, the
type 1 angiotensin receptor is activated in response to myo-
cardial stretch and stimulates ROS formation. Subsequently,
increased intracellular ROS indirectly triggers the release of
ET-1. ET-1-induced increases in intracellular calcium stimu-
late NFAT and CaMKII, culminating in hypertrophic remod-
elling (Cingolani et al., 2010). Interestingly, during PAH, pro-
hypertrophic GATA4 is also active within the right ventricle
(Park et al., 2010), suggesting that multiple ET-1 regulated
signalling pathways may be important in this condition. Sig-
nificantly, ETA receptor blockade prevents right ventricular
remodelling in an animal model (Jasmin et al., 2003), dem-
onstrating the importance of the link between PAH, right
ventricular hypertrophy and ET-1. These effects may be
responsible for the therapeutic benefit of ETA receptor antago-
nists for the treatment of PAH.
Why have ET receptor antagonists
failed in the treatment of left
ventricular hypertrophy and
congestive heart failure and where
may they provide benefit?
Despite the myriad of lines of evidence from both animal
models and humans for a role of ET-1 and ET-1-dependent
signalling pathways in left ventricular hypertrophy and con-
gestive heart failure (CHF), it is disappointing to note that
ET-1 receptor antagonists have not yet proven efficacious for
the treatment of CHF (Kirkby et al., 2008). Although initial
studies were promising (Sutsch et al., 1998), clinical trials of
the combined ETA–ETB receptor antagonist bosentan for the
treatment of CHF were halted owing to problems with liver
toxicity. Furthermore, later studies were unable to demon-
strate a reduction in the mortality or symptoms of patients
suffering from CHF when a lower dose of bosentan was
administered (Kalra et al., 2002; Kelland and Webb, 2006). A
number of explanations for the failure of this approach have
been proposed. Blockade of the ETB receptor impairs ET-1
clearance, increasing plasma ET-1 levels and allowing the
effects of ETA receptor antagonism to be overcome (Cowburn
et al., 2005). Furthermore, ETB receptor inhibition leads to
systemic vasoconstriction, a deleterious response in patients
with cardiovascular conditions (Cowburn et al., 2005). To
avoid the complicating effects of ETB receptor inhibition,
studies aiming to selectively block the ETA receptor have been
carried out (Anand et al., 2004; Cowburn et al., 2005; Leslie
et al., 2005). Although cardiac output was acutely improved,
no long-term benefit of this treatment regimen was observed
(Anand et al., 2004). However, these studies may have utilized
a dose of drug at which antagonism of the ETB receptor
cannot be completely excluded (Kelland and Webb, 2007). In
view of such limitations, it would be informative if trials were
performed using ETA receptor antagonists at a dose that more
selectively targets the ETA receptor. In addition, the results of
many of the clinical trials performed to date have not been
fully published and analysed, meaning that a thorough inter-
pretation of the data is lacking (Kelland and Webb, 2007).
Further progress will only be made by a more detailed analy-
sis of these trials. For example, there may be patient sub-
populations where ET receptor inhibition is effective. It will
also be important to gain a better understanding of the inter-
action of the ET-1 system with patient lifestyle and age.
Indeed, ET-1 levels are elevated in aged and obese popula-
tions, which may suggest that ET receptor antagonists would
provide greater benefit in these individuals. Interestingly,
improved lifestyle benefits these populations, with weight
loss and exercise reducing ET-1 levels in the obese and aged
respectively (Maeda et al., 2003; 2006). Furthermore, our
increased understanding of ET-1 biology and ET-1-induced
cellular responses may henceforth guide more intelligent
and targeted drug design. In view of the disparate effects
of ETA and ETB receptor inhibition in humans, it will be
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important to consider the influence of dimers and heterodim-
ers of the ET receptor subtypes upon downstream signalling
and pharmacology (Evans and Walker, 2008a; 2008b). More
knowledge regarding the persistence, localization and inte-
gration of these ET-1-induced responses is also required.
Agents that allow selective control of the activation of ETA
and ETB receptors and/or the individual limbs of the signal-
ling pathways they activate downstream would be particu-
larly informative. The development of biased agonists/
antagonists akin to those for the angiotensin receptor would
allow for the specific targeting of key signalling pathways
(Watts, 2010) and perhaps provide a window of opportunity
to manipulate ET-1-induced signalling for therapeutic
benefit.
Cardiac failure is the dominant cause of mortality in the
over 65 population. This population is likely to double in
number in the next 25 years; hence, future therapies will
need to be developed to tackle the increasing burden of
cardiac disease. The prominent role that ET-1 performs in the
pathological alterations in physiology and function of the
multiple cell types of the heart, in particular during ageing,
identify it as a key target for further development of thera-
peutic strategies.
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